Iron Infusion Denied by Insurance
What can I do if insurance denies an iron infusion?
A plan can deny an intravenous iron infusion because an approval was missing, because its policy says you must try oral iron first, or because of where the infusion was given. A requirement to try oral iron first is that plan's written policy, unless a Medicare rule on the notice applies. Medicare Part B can cover a drug that is not usually self-administered when it is given incident to a physician's service and the setting rules are met. This page explains the denial and the appeal. It does not promise that the infusion will be covered.
Get help with my bill →What should I read on an iron infusion denial?
Read the denial for the drug name, the date, the place it was given, and the reason. A missing approval, a requirement to try another drug first, a limit on the site of care, and a decision that the infusion is not medically necessary are different disputes. HealthCare.gov says preauthorization is a decision that a service is medically necessary, and that it is not a promise of payment. A plan may require it before a service, except in an emergency. If the notice says approval was missing, see a prior authorization denial. If it says the infusion is not medically necessary, see a medical necessity denial.
Ask the plan whether it processed the infusion as a medical benefit or as a pharmacy benefit. The appeal form can differ. A drug you pick up at a pharmacy is a different denial. See a prescription drug the plan will not cover. A specialty-drug restriction is in a specialty medication denial. If the denial is for intravenous immune globulin rather than an iron infusion, see an IVIG denial.
References: HealthCare.gov: Preauthorization · HealthCare.gov: Internal appeals
Can the plan require oral iron first?
A private plan's written policy may say you must try oral iron, or another treatment, before it covers an intravenous infusion. That requirement is the plan's policy. This page does not state a number of days or a dose, because a number, when a plan uses one, is in that policy and is not a national rule stated here. Ask for the policy. The general step-therapy appeal is in a step therapy denial. Do not ask anyone to record a trial of oral iron that did not happen. Your clinician can respond to the criterion the policy actually states, including a reason oral iron cannot be used.
Medicare Advantage step therapy for a Part B drug is a specific rule. 42 CFR 422.136 says that if a Medicare Advantage plan uses step therapy for Part B drugs, it must apply that step therapy only to new administrations, using a lookback of at least 365 days. The protocol may not include a drug the plan does not cover as a Part B drug or, for an MA-PD plan, as a Part D drug. The plan's pharmacy and therapeutics committee must review and approve the program before it is used. An off-label drug may be part of a step protocol only if the off-label indication is supported by widely used treatment guidelines or clinical literature that CMS considers to represent best practices. If the notice cites this rule, ask the plan for the lookback it used and for the covered drug it required.
A Part D exception is available only when the plan is treating the product as a Part D drug. 42 CFR 423.578(b) includes a step-therapy requirement among the formulary rules an enrollee can ask the plan to waive, and 42 CFR 423.578(e) says the exceptions process cannot be used for a drug that is not a Part D drug. The prescriber must support the request. A supporting statement does not, by itself, approve the drug. If the infusion is a Part B drug, use the Part B appeal on the notice rather than a Part D exception.
References: U.S. Department of Labor: Filing a claim for your health benefits · 42 CFR 422.136: Medicare Advantage step therapy for Part B drugs · 42 CFR 423.578: Medicare Part D exceptions process
Does the place of the infusion change Medicare coverage?
A plan's written policy may cover the infusion in a hospital outpatient department, an infusion center, a physician's office, or another site, and it may refuse a site. Ask for that policy. This page does not state a national site-of-care rule for a private plan.
Medicare Part B has setting rules for a drug that is not usually self-administered. 42 CFR 410.26 says Part B pays for services and supplies incident to a physician's or other practitioner's service, and it defines those services and supplies to include drugs or biologicals that are not usually self-administered. That section pays for them in a noninstitutional setting, which it defines as a setting other than a hospital or a skilled nursing facility, when they are an integral part of the physician's service in the course of diagnosis or treatment and the other conditions in the section are met. In general, they must be furnished under the direct supervision described in that section. 42 CFR 410.27 is the hospital rule. It says Part B pays for therapeutic outpatient hospital or critical-access-hospital services and supplies furnished incident to a physician's service, including drugs and biologicals which are not usually self-administered, when the hospital furnishes them in the hospital or in a hospital department as an integral part of the physician's service. A home infusion is not, by these two sections, the same as an office infusion or a hospital outpatient infusion. Ask which section, if any, the denial applied. 42 CFR 423.100 says a drug for which payment is available under Part A or Part B, as prescribed and dispensed or administered, is not a Part D drug.
References: 42 CFR 410.26: Services and supplies incident to a physician's service, including drugs not usually self-administered · 42 CFR 410.27: Outpatient hospital services incident to a physician's service, including drugs not usually self-administered · 42 CFR 423.100: Part D drug definition
How do I appeal an iron infusion denial?
Use the notice. For a private plan, 29 CFR 2560.503-1 gives a group health plan at least 180 days after you receive the denial to appeal, and 45 CFR 147.136 applies that standard to non-grandfathered group and individual coverage. HealthCare.gov says to file within 180 days, and to request an external review in writing within 4 months when the dispute is a medical judgment. If the notice gives a later date, use the notice. The steps are in how to appeal a health insurance denial and how to request an external review.
For Original Medicare, 42 CFR 405.942 says a redetermination must be filed within 120 calendar days after you receive the notice. Receipt is presumed five calendar days after the date on the notice unless there is evidence otherwise. The steps are in how to appeal an Original Medicare denial. For a Medicare Advantage plan, when the plan grants a request to expedite a Part B drug decision, 42 CFR 422.572 says the decision is due as expeditiously as your health requires and no later than 24 hours after the plan receives the request. The plan's appeal is in how to appeal a Medicare Advantage denial. Ask whether a clinician's call to the plan is the appeal. It does not move the deadline unless the notice says it does. Send the labs and notes the policy asked for, and your clinician's response to the step the policy named.
References: 29 CFR 2560.503-1: Claims procedure, including the 180-day appeal period · 45 CFR 147.136: Internal claims, appeals, and external review · HealthCare.gov: Internal appeals · HealthCare.gov: External review · 42 CFR 405.942: Original Medicare redetermination filing deadline · Medicare.gov: Appeals in Original Medicare · 42 CFR 422.572: Timeframes for expedited Medicare Advantage organization determinations
What this page cannot promise
This is general information, not medical or legal advice. A plan can require the oral-iron trial in its own policy. Medicare can deny an infusion that was not given incident to a physician's service in a setting the rules cover. A Part D exception does not cover a Part B drug. An appeal can leave the denial in place. Nothing on this page promises that the infusion will be covered or that a bill will be canceled.
Sources and further help
These sources provide general guidance. For a deadline or requirement that applies to you, follow your plan’s notice or the appropriate program’s current instructions.
- HealthCare.gov: Preauthorization ↗
- HealthCare.gov: Internal appeals ↗
- HealthCare.gov: External review ↗
- U.S. Department of Labor: Filing a claim for your health benefits ↗
- 29 CFR 2560.503-1: Claims procedure, including the 180-day appeal period ↗
- 45 CFR 147.136: Internal claims, appeals, and external review ↗
- 42 CFR 422.136: Medicare Advantage step therapy for Part B drugs ↗
- 42 CFR 410.26: Services and supplies incident to a physician's service, including drugs not usually self-administered ↗
- 42 CFR 410.27: Outpatient hospital services incident to a physician's service, including drugs not usually self-administered ↗
- 42 CFR 423.100: Part D drug definition ↗
- 42 CFR 423.578: Medicare Part D exceptions process ↗
- 42 CFR 422.572: Timeframes for expedited Medicare Advantage organization determinations ↗
- 42 CFR 405.942: Original Medicare redetermination filing deadline ↗
- Medicare.gov: Appeals in Original Medicare ↗
Insurer websites may ask you to select your state or sign in. If a page will not open, use the member services number on your insurance card and ask for the current appeal instructions for your plan.